Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A A Trowbridge

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
British Journal of Clinical Pharmacology|March 1, 1993
High clearance of (S)-warfarin in a warfarin-resistant subjectH O Hallak, P J Wedlund, M W Modi, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 1988
Phase I-II pilot of whole abdominal radiation and concomitant 5-FU as an adjuvant in colon cancer: a Southwest Oncology Group StudyC J Fabian, E Reddy, W Jewell, et al.
The Journal of Bone and Joint Surgery. American Volume|June 16, 2001
Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarinR H Fitzgerald, T E Spiro, A A Trowbridge, et al.
The Journal of Bone and Joint Surgery. American Volume|January 1, 1994
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial GroupC W Colwell, T E Spiro, A A Trowbridge, et al.
Archives of Internal Medicine|February 10, 1997
Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspectiveR D Hull, G E Raskob, G F Pineo, et al.
Archives of Internal Medicine|February 10, 1997
Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspectiveR D Hull, G E Raskob, D Rosenbloom, et al.
The New England Journal of Medicine|April 9, 1992
Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosisR D Hull, G E Raskob, G F Pineo, et al.
Texas Medicine|September 1, 1987
Hematology-oncology. Hematology-Oncology Workgroup, Legislative Task Force on Cancer in TexasF H Gardner, J B Alperin, J A Belli, et al.
Annals of Internal Medicine|February 15, 2001
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic diseaseG Merli, T E Spiro, C G Olsson, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
British Journal of Clinical Pharmacology|March 1, 1993
High clearance of (S)-warfarin in a warfarin-resistant subjectH O Hallak, P J Wedlund, M W Modi, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 1988
Phase I-II pilot of whole abdominal radiation and concomitant 5-FU as an adjuvant in colon cancer: a Southwest Oncology Group StudyC J Fabian, E Reddy, W Jewell, et al.
The Journal of Bone and Joint Surgery. American Volume|June 16, 2001
Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarinR H Fitzgerald, T E Spiro, A A Trowbridge, et al.
The Journal of Bone and Joint Surgery. American Volume|January 1, 1994
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial GroupC W Colwell, T E Spiro, A A Trowbridge, et al.
Archives of Internal Medicine|February 10, 1997
Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspectiveR D Hull, G E Raskob, G F Pineo, et al.
Archives of Internal Medicine|February 10, 1997
Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspectiveR D Hull, G E Raskob, D Rosenbloom, et al.
The New England Journal of Medicine|April 9, 1992
Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosisR D Hull, G E Raskob, G F Pineo, et al.
Texas Medicine|September 1, 1987
Hematology-oncology. Hematology-Oncology Workgroup, Legislative Task Force on Cancer in TexasF H Gardner, J B Alperin, J A Belli, et al.
Annals of Internal Medicine|February 15, 2001
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic diseaseG Merli, T E Spiro, C G Olsson, et al.
Pageof 3